Between August 2023 and August 2024, the number of diesel-powered cars, considered too environmentally damaging to drive in Denmark’s environmental zones, has fallen by 34%, according to a new report ...

Denmark is currently experiencing its highest rate of illness in this flu season with a high level of respiratory infections like influenza and RSV, and associated hospitalizations. This is reported ...

Novo Nordisk has acknowledged that the first phase 3 readout for ... with high-dose versions of Wegovy and oral semaglutide product Rybelsus as well as oral amycretin, which is in phase 1/2 testing.

Novo Nordisk (NVO), a pharmaceutical company, isn’t too worried about the U.S. government’s plan to negotiate prices for its ...

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street's concerns with its fourth-quarter results and 2025 outlook.

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Welcome to the full-year 2024 Novo Nordisk earnings conference call. [Operator instructions] Please be advised that today's ...

The Danish pharmaceutical company expects demand for obesity and diabetes drugs to rise, but forecasts sales growth to slow down this year. Read more.

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.